QIAGEN Expands QIAstat-Dx into Precision Medicine Through Partnership for Companion Diagnostics in Chronic Diseases
This new agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases. QIAGEN’s syndromic testing platform QIAstat-Dx enables specialty care providers to make fast decisions about patients’ eligibility for investigational precision medicines
| BioBuzz has been connecting the life science workforce since 2009. We’ve built an expansive community in the Mid-Atlantic with a national readership that spans from Massachusettes to Florida, and New York to California. For our next chapter, we’re building a proprietary talent logistics model to help employers source and hire life science talent. Learn more. |
Venlo, the Netherlands, Aug. 28, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies being developed to address chronic diseases.
Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN’s syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to potentially perform genotyping whilst patients are undergoing routine clinical examination, thus enabling fast decision making for potential suitability for AstraZeneca’s genomically targeted medicines.
“We are pleased to expand our partnership with AstraZeneca into new disease areas using our QIAstat‑Dx system and to develop together the first companion diagnostic for chronic diseases based on this platform”, said Fernando Beils, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN. “The development of the QIAstat-Dx genotyping assay with AstraZeneca showcases QIAGEN’s expertise in companion diagnostic development and commercialization, utilizing the most suitable molecular testing platform to meet the unique clinical and commercial needs of patient testing.”
The QIAstat-Dx system, designed for laboratory use, employs cost-efficient, single-use cartridges with built-in sample processing and on-board reagents. Utilizing multiplex real-time PCR, it detects and differentiates between multiple biomarkers, with results in about an hour. QIAstat-Dx also provides easy‑to‑view cycle threshold (Ct) values and amplification curves, offering additional insights not available with end-point PCR or other techniques. At the end of 2023, over 4,000 cumulative instrument placements had been made.
QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics. These can detect genetic abnormalities to provide insights that guide clinical decision-making about treatments. From polymerase chain reaction (PCR) and digital PCR (dPCR) to next-generation sequencing (NGS), QIAGEN offers an unmatched breadth of technologies, which means it can tailor products to partners’ needs.
QIAGEN has master collaboration agreements to develop and commercialize companion diagnostics with more than 30 global companies – a deep pipeline that will advance precision medicine, which tailors a patient’s treatment to the genetic profile identified by companion diagnostics testing. Furthermore, QIAGEN has a series of collaborations with Neuron23 and Helix to develop companion diagnostics in disease areas outside oncology.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
